The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Open accessAbstract
HLA-C*08:02-restricted tumor-infiltrating lymphocytes that were composed of four different T-cell clonotypes that specifically targeted KRAS G12D. However, one of these lesions had progressed on evaluation 9 months after therapy. The lesion was resected and found to have lost the chromosome 6 haplotype encoding the HLA-C*08:02 class I major histocompatibility complex (MHC) molecule. The loss of expression of this molecule provided a direct mechanism of tumor immune evasion. Thus, the infusion of CD8+ cells targeting mutant KRAS mediated effective antitumor immunotherapy against a cancer that expressed mutant KRAS G12D and HLA-C*08:02.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This approach has shown efficacy in colon cancer and NSCLC patients with mutant KRAS G12D and HLA-C*08:02 expression [88].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [88]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Tumors with mutant KRAS can express neoantigen fragments containing the oncogenic driver mutation on the major histocompatibility complex [88,89].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [88]
In the citing paper
“CD8+ TILs and TCRs in CD4+ T cells have been found to specifically recognize KRAS-related mutations, which can be further used to engineer T cells.604,605”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [604]
In the citing paper
“As noted above, peptides derived from KRASG12 variants193,194, and also from KRASQ61H/L/R (ref.198), have been demonstrated to be presented on the surface of malignant cells by various MHC I (HLA-A) molecules.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“ACT with these specific TILs resulted in regression of all seven pulmonary metastases in a patient with KRASG12D-mutant CRC from whom they had been isolated193.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Notably, loss of MHC was identified as an immune-evasion mechanism in a tumour that progressed 9 months after TIL infusion193.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Endogenous immune responses against KRAS-mutant cancer cells were first described in 2016 by Tran et al.193, who identified CD8+ TILs with T cell receptors (TCRs) that recognize MHC I (HLA-C*08:02)-presented peptide neoepitopes derived from KRASG12D.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Using CD8+ T cells that were reactive to KRASG12D mutant, a patient with CRC experienced prolonged partial response [64].”
From KRAS, a New Target for Precision Medicine in Colorectal Cancer? (2024) · cites this paper as [64]
In the citing paper
“It was found that CD8+ T cells, possessing HLA-C08:02-restricted T-cell receptors, specifically recognize the mutant KRASG12D.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“Following the intravenous administration of expanding TCRs in an ex vivo environment, a complete response was observed in lung lesions, resulting in prolonged PFS.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“A recent publication presented the relationship between the KRASG12D mutation and TCRs in a patient diagnosed with metastatic mCRC with lung metastasis [106].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“Despite the rarity of HLA-C*08:02, this study demonstrated the promise of T-cell–based immunotherapy for targeting KRASG12D and HLA-C*08:02.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [44]
In the citing paper
“Tran and colleagues described a case of a patient with metastatic colorectal cancer treated with autologous T cells specific for mutant KRASG12D, which was restricted to the major histocompatibility complex class I allele HLA-C*08:02 (44).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [44]
In the citing paper
“The anti-tumor activity of ICB has been shown to depend on CD8+ T cell, HLA class I–dependent immune activity (34–36).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,208
Self-citationCancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,737
Self-citationDudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625
Self-citationAllele-specific copy number analysis of tumors
Loo, P. V., Nord, S., Lingjærde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V., Marynen, P., Zetterberg, A., Naume, B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009843107 · Cited by 1,192
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 1,002
Characterization of KRAS Mutational Regression in Oligometastatic Patients
Ottaiano, A., d’Aragona, R. P. D. V., Trotta, A. M., Santorsola, M., Napolitano, M., Scognamiglio, G., Tatangelo, F., Grieco, P., Zappavigna, S., Granata, V., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.898561 · Cited by 17
“Cold” colorectal cancer faces a bottleneck in immunotherapy
Liu, J., Yang, M., Bai, J., Liu, Z., & Wang, X. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i2.240 · Cited by 20
Neoadjuvant personalized cancer vaccines: the final frontier?
Richard, G., Ruggiero, N., Steinberg, G. D., Martin, W. D., & Groot, A. S. D. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2303015 · Cited by 17
Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: A review
Ma, P., Jiang, Y., Zhao, G., Wang, W., Xing, S., Tang, Q., Miao, H., Fang, H., Chao, S., Yuan, F., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114224 · Cited by 17
Genetic immune escape in cancer: timing and implications for treatment
Martínez-Jiménez, F., & Chowell, D. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.11.002 · Cited by 17
Champagne, J., Nielsen, M. M., Feng, X., Navarro, J. M., Pataskar, A., Voogd, R., Giebel, L., Nagel, R., Berenst, N., Fumagalli, A., et al. (2025) · Immunity · doi:10.1016/j.immuni.2024.12.004 · Cited by 17
Cutmore, L. C., Brown, N. F., Raj, D., Chauduri, S., Wang, P., Maher, J. F., Wang, Y., Lemoine, N. R., & Marshall, J. F. (2020) · Pancreatology · doi:10.1016/j.pan.2020.02.006 · Cited by 18
Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth
Das, M., Zhou, X., Liu, Y., Das, A., Vincent, B. G., Li, J., Liu, R., & Huang, L. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100856 · Cited by 17
Burrack, A. L., Schmiechen, Z. C., Patterson, M. T., Miller, E. A., Spartz, E. J., Rollins, M. R., Raynor, J. F., Mitchell, J. S., Kaisho, T., Fife, B. T., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.151593 · Cited by 17
Neoantigen-Specific T Cells in Adoptive Cell Therapy
Tran, E. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000605 · Cited by 17
Self-citationKRAS inhibition in metastatic colorectal cancer: An update
Nusrat, M., & Yaeger, R. D. (2023) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102343 · Cited by 17
Krackhardt, A. M., Anliker, B., Hildebrandt, M., Bachmann, M. P., Eichmüller, S. B., Nettelbeck, D. M., Renner, M., Uharek, L., Willimsky, G., Schmitt, M. W., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2119-y · Cited by 18
Valentini, D., Rao, M., Meng, Q., von Landenberg, A., Bartek, J. J., Sinclair, G., Paraschoudi, G., Jäger, E., Peredo, I. H., Dodoo, E., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24955 · Cited by 17
Zhenjiang, L., Rao, M., Luo, X., Valentini, D., von Landenberg, A., Meng, Q., Sinclair, G., Hoffmann, N., Karbach, J., Altmannsberger, H., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.06.014 · Cited by 17
KRAS RENAISSANCE(S) in Tumor Infiltrating B Cells in Pancreatic Cancer
Meng, Q., Valentini, D., Rao, M., & Maeurer, M. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00384 · Cited by 17
Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer
Chodon, T., Lugade, A. A., Battaglia, S., & Odunsi, K. O. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.07.011 · Cited by 17
Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy
Margolis, N., Markovits, E., & Markel, G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.06.005 · Cited by 19
Personal tumor antigens in blood malignancies: genomics-directed identification and targeting
Penter, L., & Wu, C. J. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129209 · Cited by 17
Melanoma antigens recognized by T cells and their use for immunotherapy
Ohta, S., Misawa, A., Kyi‐Tha‐Thu, C., Matsumoto, N., Hirose, Y., & Kawakami, Y. (2023) · Experimental Dermatology · doi:10.1111/exd.14741 · Cited by 17
Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy
Biri‐Kovács, B., Bánóczi, Z., Tummalapally, A., & Szabó, I. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020452 · Cited by 16
Oncogenic drivers dictate immune control of acute myeloid leukemia
Austin, R. J., Straube, J., Haldar, R., Janardhanan, Y., Bruedigam, C., Witkowski, M. T., Cooper, L. T., Porter, A., Braun, M., Souza-Fonseca-Guimarães, F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37592-9 · Cited by 16
Neoantigens in cancer immunotherapy: quantity vs. quality
Wolf, Y., & Samuels, Y. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13483 · Cited by 16
Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies
Aparicio, B., Theunissen, P., Hervás‐Stubbs, S., Fortes, P., & Sarobe, P. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2303799 · Cited by 16
Miyauchi, T., Yaguchi, T., & Kawakami, Y. (2017) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.40.54 · Cited by 16
Induced Pluripotent Stem Cell-Derived T Cells for Cancer Immunotherapy
Patel, S. J., Yamauchi, T., & Ito, F. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.005 · Cited by 16
Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies
Rodríguez-Pascual, J., Ayuso‐Sacido, Á., & Belda-Iniesta, C. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.61 · Cited by 17
Ligon, J. A., Wessel, K. M., Shah, N. N., & Glod, J. W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.846346 · Cited by 16
KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients
Wang, S., Li, Q., Ma, P., Fang, Y., Yu, Y., Jiang, N., Miao, H., Tang, Q., Yang, Y., Xing, S., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.831382 · Cited by 16
T cells discriminate between groups C1 and C2 HLA-C
Sim, M. J. W., Stotz, Z., Lu, J., Brennan, P., Long, E. O., & Sun, P. D. (2022) · eLife · doi:10.7554/elife.75670 · Cited by 16
Tumor cells fail to present MHC-II–restricted epitopes derived from oncogenes to CD4+ T cells
Brightman, S. E., Naradikian, M. S., Thota, R. R., Becker, A., Montero, L., Bahmanof, M., Premlal, A. L. R., Greenbaum, J., Peters, B., Cohen, E. E. W., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.165570 · Cited by 17
Awakening immunity against cancer: a 2017 primer for clinicians
Jain, A., Zhang, Q., & Toh, H.-C. (2017) · 癌症：英文版 · doi:10.1186/s40880-017-0233-4 · Cited by 16
T-Cell Transfer Therapy Targeting Mutant KRAS.
Rosenberg, S. A., Tran, E., & Robbins, P. F. (2017) · PubMed · Cited by 16
Self-citationT-Cell Immunotherapy against Mutant KRAS for Pancreatic Cancer
Melief, C. J. M. (2022) · New England Journal of Medicine · doi:10.1056/nejme2204283 · Cited by 16
Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering
Chen, X. T., Mao, Z., Kolawole, E. M., Persechino, M., Jude, K. M., Ogishi, M., Mo, K. C., McLaughlin, J., Cheng, D., Xiang, X., et al. (2026) · Science · doi:10.1126/science.adx3162 · Cited by 17
Nasioudis, D., Llauradó, M., Wong, N. K. Y., Powell, D. J., Mills, G. B., Westin, S. N., Fader, A. N., Carey, M. S., & Simpkins, F. A. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.08.007 · Cited by 16
Wang, X., Yuan, Z., Li, Z., He, X., Zhang, Y., Wang, X., Su, J., Wu, X., Li, M., Du, F., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1354313 · Cited by 15
Reassessing human MHC-I genetic diversity in T cell studies
Slieker, R. C., Warmerdam, D. O., Vermeer, M. H., van Doorn, R., Heemskerk, M. H. M., & Scheeren, F. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-58777-2 · Cited by 15
Immunotherapies targeting the oncogenic fusion gene CLDN18-ARHGAP in gastric cancer
Wang, Y., Wang, H., Shi, T., Song, X., Zhang, X., Zhang, Y., Wang, X., Che, K., Luo, Y., Yu, L., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00120-3 · Cited by 15
Advances and Challenges in RAS Signaling Targeted Therapy in Leukemia
Chen, Y., Yin, Z., Westover, K. D., Zhou, Z., & Shu, L. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0504 · Cited by 15
Cell-based immunotherapies for solid tumors: advances, challenges, and future directions
Zhao, T., You, J., Wang, C., Li, B., Liu, Y., Shao, M., Zhao, W., & Zhou, C. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1551583 · Cited by 15
Neoantigen-Based Immunotherapy in Lung Cancer: Advances, Challenges and Prospects
Li, X., Zhu, Y., Xue, Y., Chen, T., Sun, X., & Shi, H. (2025) · Cancers · doi:10.3390/cancers17121953 · Cited by 15
Zhang, C., Palashati, H., Tan, Q., Ku, W., Yu, M., Xiong, H., & Lu, Z. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy116 · Cited by 15
Adoptive T-Cell Therapy for Solid Malignancies
Jafferji, M. S., & Yang, J. C.-H. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.012 · Cited by 15
Diverse Neoantigens and the Development of Cancer Therapies
Srivastava, R. M., Purohit, T. A., & Chan, T. A.-T. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2019.12.001 · Cited by 15
Ottaiano, A., Nasti, G., Santorsola, M., Altieri, V. M., Fruscio, G. D., Circelli, L., Luce, A., Cossu, A. M., Scognamiglio, G., Perri, F., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.632962 · Cited by 15
Reimann, H., Nguyen, A., Sanborn, Z., Vaske, C. J., Benz, S. C., Niazi, K., Rabizadeh, S., Spilman, P., Mackensen, A., Ruebner, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002605 · Cited by 15
Çınar, Ö., Brzezicha, B., Grunert, C., Kloetzel, P. M., Beier, C., Peuker, C. A., Keller, U. B., Pezzutto, A., & Busse, A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002410 · Cited by 16
Harnessing the Immune System to Fight Multiple Myeloma
Krejcik, J., Barnkob, M. B., Nyvold, C. G., Larsen, T. S., Barington, T., & Abildgaard, N. (2021) · Cancers · doi:10.3390/cancers13184546 · Cited by 16
Bräunlein, E., Lupoli, G., Abualrous, E. T., Krätzig, N. D. A., Krätzig, N. D. A., Füchsl, F., Wietbrock, L., Lange, S., Engleitner, T., Lan, H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002754 · Cited by 15
Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy
Nagayama, S., Low, S., Kiyotani, K., & Nakamura, Y. (2021) · Cancers · doi:10.3390/cancers13194803 · Cited by 16
Emerging drug targets for colon cancer: A preclinical assessment
Crutcher, M. M., Baybutt, T. R., Kopenhaver, J. S., Snook, A. E., & Waldman, S. A. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2039119 · Cited by 15
Kumar, S. U., Balasundaram, A., Hephzibah Cathryn, R., Varghese, R. P., Ramamoorthy, S., Ramanathan, G., Younes, S. N., Zayed, H., & Doss, C. G. P. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105701 · Cited by 15
Precision Medicine and Distributive Justice
Fleck, L. M. (2022) · doi:10.1093/oso/9780197647721.001.0001 · Cited by 16
Babel, N., Stervbo, U., Reinke, P., & Volk, H. (2019) · Transplantation · doi:10.1097/tp.0000000000002776 · Cited by 15
Tailoring precision immunotherapy: coming to a clinic soon?
Han, S., Shuen, T. W. H., Wang, W.-W., Nazim, E., & Toh, H. C. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000631 · Cited by 16
Actualización general de inmunoterapia en cáncer
Reyes, S. J., González, K. B., Rodríguez, C., Navarrete-Muñoz, C., Salazar, A. P., Villagra, A., Caglevic, C., & Hepp, M. I. (2020) · Revista médica de Chile · doi:10.4067/s0034-98872020000700970 · Cited by 15
Advances in adoptive cellular therapy for colorectal cancer: A narrative review
Yi, X., & Hu, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6196 · Cited by 14
Harnessing TCR repertoires: predictive insights and therapeutic monitoring in cancer immunotherapy
Chiffelle, J., Genolet, R., Michielin, O. A., & Harari, A. (2025) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2025.101076 · Cited by 14
Aoki, T., Nishida, N., & Kudo, M. (2021) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554211056853 · Cited by 15
Tissue-resident memory T cells in gastrointestinal tumors: turning immune desert into immune oasis
Liang, M., Wang, X., Cai, D., Guan, W., & Shen, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1119383 · Cited by 15
Aoki, T., Kudo, M., Ueshima, K., Morita, M., Chishina, H., Takita, M., Hagiwara, S., Ida, H., Minami, Y., Tsurusaki, M., et al. (2023) · Liver Cancer · doi:10.1159/000531024 · Cited by 14
Heterogeneity of the tumor immune microenvironment and clinical interventions
Jin, Z., Zhou, Q., Cheng, J., Jia, Q., & Zhu, B. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1015-9 · Cited by 14
Ade, C. M., Sporn, M., Das, S., Yu, Z., Hanada, K., Qi, Y. A., Maity, T. K., Zhang, X., Guha, U., Andrésson, Þ., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007097 · Cited by 14
Xiong, J., Fu, Y., Huang, J., Wang, Y., Jin, X., Wan, X., Huang, L., & Huang, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1265525 · Cited by 14
Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations
Linette, G. P., Bear, A. S., & Carreno, B. M. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1212 · Cited by 14
CD8α Structural Domains Enhance GUCY2C CAR-T Cell Efficacy
Baybutt, T. R., Entezari, A. A., Caspi, A., Staudt, R. E., Carlson, R. D., Waldman, S. A., & Snook, A. E. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2398801 · Cited by 14
The future of cellular therapy for the treatment of renal cell carcinoma
Chaoul, N., Lauricella, E., Giglio, A., D’Angelo, G., Ganini, C., Cives, M., & Porta, C. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2418321 · Cited by 14
Yee, C., & Lizee, G. A. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000255 · Cited by 14
Verdegaal, E. M. E., & van der Burg, S. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01113 · Cited by 16
CD8+ T Cells in Immunotherapy, Radiotherapy, and Chemotherapy
Wang, W., Green, M. D., Liu, J. R., Lawrence, T. S., & Zou, W. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_3 · Cited by 14
Intracellular targets as source for cleaner targets for the treatment of solid tumors
Gerber, H., Sibener, L. V., Lee, L. J., & Gee, M. H. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.07.015 · Cited by 14
Cancer Immunotherapy – The Target is Precisely on The Cancer and Also Not
Koo, S., Wang, W. W., & Toh, H. C. (2018) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v47n9p381 · Cited by 14
T Cell Receptor Engineered Lymphocytes for Cancer Therapy
Rollins, M. R., Spartz, E. J., & Stromnes, I. M. (2020) · Current Protocols in Immunology · doi:10.1002/cpim.97 · Cited by 15
Shinkawa, T., Tokita, S., Nakatsugawa, M., Kikuchi, Y., Kanaseki, T., & Torigoe, T. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1870062 · Cited by 15
Shenderov, E., Kandasamy, M., Gileadi, U., Chen, J., Shepherd, D., Gibbs, J. S., Prota, G., Silk, J. D., Yewdell, J. W., & Cerundolo, V. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002544 · Cited by 14
What’s next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination
Redwood, A., Dick, I. M., Creaney, J., & Robinson, B. W. S. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2038403 · Cited by 14
HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab
Ladányi, A., Hegyi, B., Balatoni, T., Liszkay, G., Rohregger, R., Waldnig, C., Dudás, J., & Ferrone, S. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610297 · Cited by 14
Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy
Rosati, G., Aprile, G., Colombo, A., Cordio, S. S., Giampaglia, M., Cappetta, A., Porretto, C. M., Stefano, A. D., Bilancia, D., & Avallone, A. (2022) · Biomedicines · doi:10.3390/biomedicines10051035 · Cited by 14
Targeting KRAS : Crossroads of Signaling and Immune Inhibition
Kato, S., Fujiwara, Y., & Hong, D. S. (2022) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-22-5 · Cited by 15
Cancer Immunotherapy Beyond Checkpoint Blockade
Welty, N. E., & Gill, S. I. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.11.006 · Cited by 16
Caughey, B. A., & Strickler, J. H. (2023) · Drugs · doi:10.1007/s40265-023-01980-8 · Cited by 15
Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy
Zhou, S., Wei, J., Su, S., Chen, F., Qiu, Y., & Liu, B. (2017) · Journal of Cancer · doi:10.7150/jca.19501 · Cited by 14
Schmidt, J. R., Rücker‐Braun, E., Heidrich, K., Bonin, M. V., Stölzel, F., Thiede, C., Middeke, J. M., Ehninger, G., Bornhäuser, M., Schetelig, J., et al. (2018) · Proteomes · doi:10.3390/proteomes6010011 · Cited by 14
Chimeric Antigen Receptor T-Cell Therapy: A Beacon of Hope in the Fight Against Cancer
Tariq, S. M., Haider, S. A., Hasan, M., Tahir, A., Khan, M., Rehan, A., & Kamal, A. (2018) · Cureus · doi:10.7759/cureus.3486 · Cited by 14
Targeting Neoantigens for Personalised Immunotherapy
Pritchard, A. L. (2018) · BioDrugs · doi:10.1007/s40259-018-0267-4 · Cited by 14
A Journey in Science: Immersion in the search for effective cancer immunotherapies
Rosenberg, S. A. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00321-3 · Cited by 14
Self-citationNel, A. E., Luo, L., Liao, Y., & Wang, X. (2025) · ACS Nano · doi:10.1021/acsnano.5c14753 · Cited by 13
A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial
Baretti, M., Kirk, A. M., Ladle, B. H., Kamdar, Z. P., Bendinelli, K. J., Ho, W. J., Adhikari, S., Clark, N. A., Sundararaman, B., Wang, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03995-y · Cited by 16
Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches
Huang, R., Bi, Z., Hu, S., Zhang, Q., Su, X., & Zhang, W. (2023) · Biomarker Research · doi:10.1186/s40364-023-00478-5 · Cited by 15
Organoids as an Enabler of Precision Immuno-Oncology
Zhao, J., Fong, A. S. W., Seow, S. V., & Toh, H. C. (2023) · Cells · doi:10.3390/cells12081165 · Cited by 13
Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response
Nemunaitis, J. J., Stanbery, L., Willoughby, D., Bognar, E., Brun, S., Walter, A., Monk, B. J., Rocconi, R. P., Choucair, K., & Coleman, R. L. (2023) · Cancers · doi:10.3390/cancers15235616 · Cited by 14
Chhichholiya, Y., Singh, H. V., Vashistha, R., Singh, S., & Munshi, A. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104250 · Cited by 14
The mast cell-T lymphocyte axis impacts cancer: Friend or foe?
Kannen, V., Grant, D. M., & Matthews, J. B. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216805 · Cited by 14
Targeting KRAS Oncogene for Patients With Colorectal Cancer: A New Step Toward Precision Medicine
Şahin, İ. H., Saridogan, T., Ayasun, R., Syed, M. P., Gorantla, V. C., Malhotra, M. K., Thomas, R. A., Rhee, J. C., Zhang, J. Y., Hsu, D. J., et al. (2024) · JCO Oncology Practice · doi:10.1200/op.23.00787 · Cited by 13
Shen, M., Chen, S., Han, X., Hao, Y., Wang, J., Luo, L., Chen, T., Wang, B., Zou, L., Zhang, T., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03729-y · Cited by 13
Public neoantigens in breast cancer immunotherapy (Review)
Sueangoen, N., Thuwajit, P., Yenchitsomanus, P., & Thuwajit, C. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5388 · Cited by 13
Dowdell, A. K., Meng, R., Vita, A., Bapat, B., Hanes, D. A., Chang, S., Harold, L., Schmidt, M., Wong, C., Poon, H., et al. (2024) · JCO Oncology Practice · doi:10.1200/op.24.00226 · Cited by 13
The Landmark Series: Therapeutic Cancer Vaccine Strategies for Cold Tumors
Blair, A. B., Zheng, L., & Soares, K. C. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17281-1 · Cited by 13
Neoantigen prediction from genomic and transcriptomic data
Battaglia, S. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.10.003 · Cited by 13
Mandriani, B., Pellè, E., Pezzicoli, G., Strosberg, J., Abate‐Daga, D., Guarini, A., Cives, M., & Porta, C. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102288 · Cited by 13
Metadata
- Authors
- Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., Kriley, I. R., & Rosenberg, S. A.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12-08
- Volume
- 375
- Issue
- 23
- Pages
- 2255-2262
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5178827
- OpenAlex
- W2559953355
- Cited by
- 1,368
- References
- 27
- Citations by year
- 2026: 96 · 2025: 132 · 2024: 129 · 2023: 162 · 2022: 162 · 2021: 183 · 2020: 149 · 2019: 134 · 2018: 118 · 2017: 98 · 2016: 3
- FWCI
- 71.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (Z01BC010984)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- tumor-infiltrating lymphocytes, mutant KRAS, KRAS G12D, CD8+ T cells, tumor immune evasion, MHC class I loss, cancer immunotherapy
- MeSH terms
- Female, Flow Cytometry, Humans, Lung, Lung Neoplasms, Middle Aged, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), CD8-Positive T-Lymphocytes, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
